STOCK TITAN

OmniAb, Inc. - $OABI STOCK NEWS

Welcome to our dedicated page for OmniAb news (Ticker: $OABI), a resource for investors and traders seeking the latest updates and insights on OmniAb stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect OmniAb's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of OmniAb's position in the market.

Rhea-AI Summary

OmniAb, Inc. (NASDAQ: OABI) is set to participate in five investor conferences in May, including the RBC Capital Markets Global Healthcare Conference, H.C. Wainwright BioConnect Investor Conference, Benchmark Virtual Healthcare House Call Investor Conference, Craig-Hallum Institutional Investor Conference, and Leerink Partners Healthcare Crossroads Conference. These events will provide opportunities for management to engage with investors, present fireside chats, participate in one-on-one meetings, and share insights on the company's future prospects.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.7%
Tags
conferences
-
Rhea-AI Summary
OmniAb, Inc. (NASDAQ: OABI) will report financial results for the first quarter of 2024 on May 9th, after the U.S. financial markets close. A conference call will be held the same day at 4:30 p.m. Eastern time to discuss the results and business updates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.21%
Tags
conferences earnings
-
Rhea-AI Summary
OmniAb, Inc. (NASDAQ: OABI) reported financial results for Q4 2023 and full year 2023, highlighting revenue decreases, increased R&D expenses, and net losses. Despite challenges, the company expanded partnerships, launched new technologies, and remains optimistic for future growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.17%
Tags
Rhea-AI Summary
OmniAb, Inc. (OABI) will release financial results for the three and 12 months ending December 31, 2023, on March 20, 2024. A conference call discussing the results and business updates will follow. Details include the conference date, time, call-in numbers, and webcast information.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.37%
Tags
conferences earnings
-
Rhea-AI Summary
OmniAb, Inc. (OABI) will participate in two investor conferences in March - TD Cowen 44th Annual Healthcare Conference and Leerink Partners Global Biopharma Conference. Management will engage in fireside chats and one-on-one meetings with investors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.77%
Tags
conferences
-
Rhea-AI Summary
OmniAb, Inc. (Nasdaq: OABI) presented new scientific data on its OmnidAb™ platform, the industry’s first transgenic chicken host system producing single domain antibodies, at the 2023 Antibody Engineering & Therapeutics Conference. The OmnidAb platform offers significant benefits due to its use of an optimized human scaffold combined with efficient in vivo affinity maturation, providing a functionally diverse immune repertoire that is unavailable from mammalian systems.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
OmnioAb, Inc. (Nasdaq: OABI) highlights launch of OmnidAb, the industry's first transgenic chicken producing single domain antibodies in virtual event. Company's CEO, Matt Foehr, emphasizes significant progress and infrastructure in place for growth. Senior management presents business updates and new technology platforms, including OmnidAb. The technology offers optimized single-domain humanized framework, distinct epitopes, and favorable developability profiles.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.75%
Tags
none
-
Rhea-AI Summary
OmniAb, Inc. (NASDAQ: OABI) reported Q3 2023 financial results, highlighting a $5.5 million revenue and $15.7 million net loss. The company's partner portfolio grew to 314 active programs, up from 291 at the beginning of the year. OmniAb also announced a Research & Technology Virtual Event showcasing their new OmnidAb™ technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.61%
Tags
-
Rhea-AI Summary
OmniAb, Inc. (NASDAQ: OABI) will be participating in two investor conferences in November. They will be attending the Stifel 2023 Healthcare Conference on November 14-15, 2023, where they will participate in a fireside chat and have one-on-one meetings with investors. They will also be attending the 14th Annual Craig-Hallum Alpha Select Conference on November 16, 2023, where they will host one-on-one meetings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.33%
Tags
conferences
Rhea-AI Summary
OmniAb, Inc. (NASDAQ: OABI) appoints Steve Love to its Board of Directors. Mr. Love has over 30 years of financial experience and will serve on OmniAb's Audit Committee as Chair. With this appointment, the OmniAb Board now has seven directors, including five independent directors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.88%
Tags
management
OmniAb, Inc.

Nasdaq:OABI

OABI Rankings

OABI Stock Data

539.81M
95.17M
4.9%
74.48%
4.39%
Testing Laboratories
Professional, Scientific, and Technical Services
Link
United States of America
EMERYVILLE

About OABI

the omniab discovery platform provides pharmaceutical industry partners access to diverse antibody repertoires and high-throughput screening technologies to enable discovery of next-generation therapeutics.